Cartesian Therapeutics Announces New Employment Inducement Grants
New Strong Sell Stocks for July 1st
Cartesian Therapeutics Announces New Employment Inducement Grant
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $38.50 Average Price Target from Brokerages
Analyzing Cartesian Therapeutics (NASDAQ:RNAC) and Applied Therapeutics (NASDAQ:APLT)
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $38.50 Average PT from Brokerages
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $38.50 Consensus Target Price from Brokerages
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
Cartesian Therapeutics Announces New Employment Inducement Grants
Contrasting Beyond Air (NASDAQ:XAIR) & Cartesian Therapeutics (NASDAQ:RNAC)
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis
Cartesian Therapeutics Announces New Employment Inducement Grants
Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian (RNAC) Q2 Revenue Drops 99%
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Substantial Insider Buying: American Express, Asana, and More
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
Cartesian Therapeutics: Uncertainty Remains